1Kazuyuki S, Hiroshi K. Heparin and heparin sulfate biosynthesis [ J]. IUBMB Life ,2002,54 : 163 - 175.
2Lindahl U. Heparin'-from anticoagulant drug into the new biology [ J]. Glyeoconjugate Journal,2000,17:597 - 605.
3Falanga A, Marohetti M. Heparin in tumor progression and metastatic dissemination [ J ]. Semin Thromb Hemost, 2007,33 : 688 - 94.
4国家药典编委会.中华人民共和国药典[M].2部.北京:中国医药科技出版社,2010:附录118.
5Keire D A,Mans D J,Ye Hong-ping,et al. Assay of possible economically motivated additives or native impurities levels in heparin by i HNMR, SAX - HPLC, and anticoagulation time approaches [ J ]. J Pharm Biomed Anal,2009,52 (5) : 656 - 664.
6Kishimoto T K, Viswanathan K, Ganguly T,et al. Contaminated heparin aassoeiated with adverse clinical events and activation of the contact system[ J ]. N Engl J Med, 2008,358 ( 23 ) : 2457 - 2467.
7Keire D A,Trehy M L,Reepmeyer J C,et al. Analysis of crude heparin by l HNMR, capillary electmphoresis, and stmng-anion- exchange-HPLC for contamination by over sulfated chondmitin sulfate [ J ]. J pHarm Biomed Anal,2010,51 (4) :921 - 926.
